glp-1 obesity drug news today october 23 2025 RA Weight Loss Drugs May Carry Untold Ocular Burden ADA '26: Lilly's dominance, Pfizer's

The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD420251039831

33 The basic information of the article was recorded, including the first author, publication date, sample size, average age, and sex of the patients, type of study design, diagnostic criteria for AD, intervention methods, and assessment methods of cognitive function

The funders of this study had no role in design and conduct of the study

While GLP-1 medications may seem relatively new to the market, theyve actually been used for the treatment of Type 2 diabetes since 2005, when Byetta became the first FDA-approved GLP-1 medication

Soliqua 100/33 (insulin glargine and lixisenatide injection): Prescribing information

Zepbound (tirzepatide) Approved - A once-weekly injectable medication approved by the FDA in November 2023 for chronic weight management